BFEC
VYGR icon

Benjamin F. Edwards & Company’s Voyager Therapeutics VYGR Stock Holding History

Benjamin F. Edwards & Company’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,220
Closed -$19K – 2264
2023
Q4 		$19K Hold
2,220
– – ﹤0.01% 1500
2023
Q3 		$17K Buy
+2,220
New +$20.3K ﹤0.01% 1291

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Benjamin F. Edwards & Company's VYGR Position: Q1 2024 in Review

Benjamin F. Edwards & Company sold out of Voyager Therapeutics (VYGR) in Q1 2024, closing a stake of 2,220 shares — an estimated $19K sold.

Benjamin F. Edwards & Company first reported a position in VYGR in Q3 2023 and held it in 2 quarters. The position peaked at $19K in Q4 2023. 132 funds tracked by Wall St. Rank hold VYGR as of Q1 2024.

  • Benjamin F. Edwards & Company reported no remaining Voyager Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 2,220 Voyager Therapeutics shares in Q1 2024, an estimated $19K.
  • Benjamin F. Edwards & Company first reported a position in Voyager Therapeutics in Q3 2023 and held it in 2 quarters.
  • Benjamin F. Edwards & Company's Voyager Therapeutics position peaked at $19K in Q4 2023.
  • 132 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2024, filed 29 Apr 2024.